Medpace Holdings (MEDP) EPS (Weighted Average and Diluted) (2015 - 2026)

Medpace Holdings has reported EPS (Weighted Average and Diluted) for 12 years, with the latest figure at $4.28 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 16.62% year-over-year to $4.28; the trailing twelve-month figure through Mar 2026 stood at $15.88 (up 21.22% YoY), and the FY2025 full-year result was $15.28, up 20.98% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at $4.28, down from $4.64 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $4.64 in Q4 2025, with the low at $1.46 in Q2 2022.
• Historically, EPS (Weighted Average and Diluted) has averaged $2.84 across 5 years, with a median of $2.75 in 2024.
• Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) jumped 59.09% — and 2023, when it increased 8.29%.
• Medpace Holdings' EPS (Weighted Average and Diluted) stood at $2.1 in 2022, then advanced by 17.14% to $2.46 in 2023, then surged by 49.19% to $3.67 in 2024, then rose by 26.43% to $4.64 in 2025, then decreased by 7.76% to $4.28 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $4.28 (Q1 2026), $4.64 (Q4 2025), and $3.86 (Q3 2025), per Business Quant data.